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Development of modiﬁed nucleosides that have supremely high anti-HIV
activity and low toxicity and prevent the emergence
of resistant HIV mutants
By Hiroshi OHRUI*1,†
(Communicated by Takao SEKIYA, M.J.A.)
Abstract: An idea to use 4′-C-substituted-2′-deoxynucleoside derivatives was proposed
based on a working hypothesis to solve the problems of existing acquired immune deﬁciency
syndrome chemotherapy (highly active antiretroviral therapy). Subsequent studies have success-
fully proved the validity of the idea and resulted in the development of 2′-deoxy-4′-C-ethynyl-
2-ﬂuoroadenosine and 2′-deoxy-4′-C-ethynyl-2-chloroadenosine, nucleoside reverse transcriptase
inhibitors, which have supremely high activity against all human immunodeﬁciency viruses
including multidrug-resistant HIV and low toxicity.
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Preface
I would like to describe the development of 2′-
deoxy-4′-C-ethynyl-2-ﬂuoroadenosine and its 2-chlo-
ro congener that have high anti-HIV activity and low
toxicity and prevent the emergence of resistant HIV
mutants, because the development is one of my
contributions to the collaboration studies, with Dr.
Takeshi Kitahara, a Professor Emeritus of The
University of Tokyo, on Invention and Application
of Molecules with Novel Biological Functions for
receiving The Japan Academy Prize in 2010.
Introduction
Since the discovery of 3′-C-azido-3′-deoxythymi-
dine (AZT) as the anti-human immunodeﬁciency virus
(HIV) agent by Dr. Hiroaki Mitsuya in 1985,1) many
2′,3′-dideoxy nucleoside (ddN) analogs have been
developed as nucleoside reverse transcriptase inhibitors
(NRTIs ) .H o w e v e r ,r e s i s t a n tHIV mutants against all
these NRTIs have emerged rapidly and easily.
A highly active antiretroviral therapy
(HAART) using two or more nucleoside reverse
transcriptase inhibitors (NRTIs) and protease in-
hibitors has dramatically improved the quality of life
and prognosis of patients infected by HIV.2),3)
However, the existing HAART has several critical
problems that remain to be solved. These problems
include: (i) the emergence of new drug-resistant HIV
mutants, (ii) the need to take large dosages of drugs,
and (iii) drug side eﬀects. Therefore, the development
of new, highly potent anti-HIV drugs that prevent
the emergence of drug-resistant mutants and have
few side eﬀects is urgently needed.
These problems prompted me to speculate on
the reason for the emergence of HIV mutant
resistant to clinical NRTIs, which belong to the
family of ddN. I proposed a working hypothesis for
the chemical structure of a new highly anti-HIV
active NRTIs that might prevent the emergence of
drug-resistant mutants. The design of 4′-C-substi-
tuted-2′-deoxynucleoside (4′SdN) was based on the
working hypothesis. The working hypothesis for the
decrease of toxicity of nucleoside derivatives was also
proposed based on my past ﬁndings of the relation-
ship between the biological activity and structure
of nucleoside derivatives. Study on the synthesis
and biological evaluation of 4′SdNs have proved the
validity of the working hypotheses and resulted in the
development of 2′-deoxy-4′-C-ethynyl-2-ﬂuoroadeno-
sine (4′Ed2FA) and 2′-deoxy-4′-C-ethynyl-2-chloro-
adenosine (4′Ed2ClA) (Fig. 1). These NRTIs are
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©2011 The Japan Academysupremely active against all HIVs and have pre-
vented the emergence of drug-resistant mutants for
many years since their development and expected to
prevent the emergence of drug-resistant mutants,
have a low toxicity, and stable to enzymatic
catabolism. Hence, 4′Ed2FA and 4′Ed2ClA are
important keys for their further development of
potential therapeutics to solve the problems being
encountered by the present HAART.
Working hypotheses of the study
1. Design of the nucleoside derivatives that
might be eﬀective for drug-resistant HIV-mu-
tants and possibly prevent the emergence of new
drug-resistant HIV mutants. The structures of
the clinical NRTIs are shown in Fig. 2. All belong to
the ddN family. The ddN structure has been
considered essential for the nucleoside derivatives to
be the chain terminator of the reverse transcriptase
(RT)-catalyzed biosynthesis of proviral DNA.
However, HIV mutants resistant to all ddN-NRTIs
have emerged rapidly and easily.
The emergence of HIV-mutants resistant to
ddNs indicates that HIV-mutants acquired the
ability to distinguish ddNs from physiological 2′-
deoxy nucleosides (dNs) and do not accept ddNs into
the active center of RT and/or cut oﬀ the incorpo-
rated ddNs from the proviral DNA terminus.
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Fig. 1. Structures of 2′-deoxy-4′-C-ethynyl-2-ﬂuoroadenosine
(4′Ed2FA) and its 2-chloro congener (4′Ed2ClA).
O HO N
NH
O
O
N3
H3C
O HO N
N
O
NH2
NH
N N
N
O HO
O
O HO N
NH
O
O
H3C
O
S
N
N
O HO
R
N
N
N
HO
NH
NH2 N
NH2
N
N
N
NH2
N
O P
O
i-prOCOH2CO
O
i-prOCOH2CO
O
CH3
O HO
OH
O HO
OH
R
R=H:lamivudine(3TC)
R=F:emtricitabine(FTC)
abacavir(ABC)
HIV
Clinical NRTIs
tenofovir disoproxil fumarate(TDF)
stavudine(d4T) zidovudine(AZT) didanosine(ddI)
Base
dN
Base
4'SdN
HIV
can not discriminate
zalcitabine(ddC)
discriminate
Fig. 2. Structures of clinical nucleosides reverse transcriptase inhibitors (NRTIs), physiologic 2′-deoxynucleoside (4′SdN). HIV F human
immunodeﬁciency virus; dN F 2′-deoxynucleoside, 4′SdN F 4′-C-substituted-2′-deoxynucleoside.
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prevent the emergence of drug-resistant HIV mu-
tants must satisfy the following two conditions.
1. To prevent the discrimination by HIV, the
modiﬁed nucleosides should have a structure
resembling those of physiologic nucleosides as
closely as possible so that RT mistakes them for
physiologic nucleosides. Since the striking diﬀer-
ence of the ddN and dN is whether they have 3′-
OH, the modiﬁed nucleosides must have 3′-OH.
2. In spite of having 3′-OH, the nucleoside must be
the chain terminator of RT-catalyzed biosyn-
thesis of proviral DNA.
Based on the following hypothesis, 4′SdN
(Fig. 2) was designed as a nucleoside that could
satisfy the above mentioned two conditions:
① It would be diﬃcult for HIV to discriminate
4′SdN from dN because 4′SdN has all the
functional groups of dN.
② The introduction of a substituent at 4′-
position makes the 3′-OH into a very un-
reactive neopentyl-type secondary alcohol.
Thus, the 3′-OH of 4′SdN will be used for
HIV to mistake 4′SdN for dN, but is too
unreactive to be used for the elongation of
proviral DNA by RT. Therefore, 4′SdNs
could be the chain terminators of proviral
DNA biosynthesis.
③ Steric hindrance between 3′-OH and 4′-sub-
stituent changes the conformation of the
furanose ring of 4′SdN preferably to the 3′-
endo conformation (N-type). This results
in 4′SdN being less susceptible to both
acidic and enzymatic glycolysis than dN and
ddN. (In glycolysis, the oxygen atom of the
furanose ring participates to form a coplanar
oxocarbonium ion, but the conformational
change makes it diﬃcult for the oxygen atom
to form a coplanar oxocarbonium ion.)
④ Further, the electron-withdrawing 3′-OH
makes 4′SdN more acid stable than does
ddN even with purines. Thus, various purine
derivatives can be made in this way.
⑤ The lipophilic substituent at the 4′-position
imparts more lipophilicity to 4′SdNs, thus
enabling them to penetrate the cell membrane
eﬃciently. This possibly enhances their bio-
availability.
2. Method of decreasing the toxicity of
nucleoside drugs based on my past ﬁndings of
the relationship between the biological activity
and structure of nucleoside derivatives. If DNA
polymerases also mistake 4′SdN for dN, 4′SdN
should be highly toxic. However, ddNs have been
used as anti-HIV drugs, meaning that DNA
polymerases hardly accept ddNs as their substrates.
Thus, the ability of DNA polymerases to distinguish
substrate is superior to that of RT. (The substrate
selectivity between DNA polymerases and RT must
be diﬀerent.)
The structures of the representative nucleoside
antibiotic are shown in Fig. 3.4) Most of them are
nucleoside derivatives modiﬁed at one site of the
physiological nucleosides. Though they are highly
active against microorganisms, they are highly toxic,
too. Therefore, they can not be clinically used. In the
1960s and 1970s, many organic chemists synthesized
nucleoside derivatives modiﬁed at two or more
positions of physiologic nucleosides expecting to get
nucleoside derivatives having new and/or higher
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Fig. 3. Structures of the representative nucleoside antibiotics. The arrows point at the modiﬁed.
Highly anti-HIV active modiﬁed nucleosides No. 3] 55biological activity. However, none of these modiﬁed
nucleosides exhibited antimicrobial activity. These
results indicated that intracellular enzymes do not
recognize the nucleoside derivatives modiﬁed at two or
more positions of physiologic nucleosides as sub-
strates. Thus, there is a chance of decreasing the
toxicity of 4′SdNs further by additional modiﬁcation.
Results and discussion
Examination of the validity of the working
hypotheses with 4′-C-methyl nucleosides. At
ﬁrst, to examine the validity of the working
hypothesis, 4′-C-methyl-nucleosides (4′MNs), 4′-C-
methyl-2′-deoxynucleosides (4′MdNs), 4′-C-methyl-
2′,3′-dideoxynucleosides (4′MddNs), and 4′-C-meth-
yl-2′,3′-didehydrodideoxynucleosides (4′Md4Ns)
(Table 1) were synthesized and evaluated for their
biological activity.5),6) 4′MdN showed remarkable
biologoical activity (both anti-HIV activity and
toxicity), but 4′MddN and 4′Md4N did not show
notable biological activity (Table 1). 4′MNs did not
show any anti-HIV activity at all.
These results indicate the importance of the 3′-
OH for biological activity. Further, we demonstrated
that 5′-O-triphosphate of both 4′-C-methyl-2′-deoxy-
cytidine (4′MdCTP) and 4′-C-methyl-D-arabino-
furanosyl cytidine (4′MAraCTP) are the chain
terminator of calf thymus DNA polymerase , and
recombinant rat DNA polymerase O.7) These results
indicate that 4′SdN was an NRTI, although further
study of 4′MdCTP with RT was not performed.
They were synthesized by glycosidation of 1,2-di-
O-acetyl-3,5-di-O-benzyl-4-C-methyl-D-ribo-furanose
(4), prepared from D-glucose through 3-O-benzyl-4-C-
hydroxymethyl-1,2-O-isopropylidene-,-D-ribo-fura-
nose (1),8) and nucleobases and then deoxygenation of
the hydroxyl groups of 4′MNs (Scheme 1).
It should be noted that the 4′-C-methyl ribo-
furanose derivatives took longer reaction time to
complete the glycosidation reaction with silylated
nucleoside bases than that of normal ribo-furanose
derivatives, indicating the lower reactivity of the 4′-
C-methyl ribo-furanoses than normal ribo-furanoses.
In addition, the 3J1′,2′ values of 4′-C-methyl ribo-
furanosyl nucleoside were larger (4–7Hz) than those
of the normal O-ribo-nucleoside (0–1Hz), indicating
the change of the conformation of the furanose ring of
the 4′-C-substituted nucleosides.
Structure–activity relationship (SAR) of
4′SdNs. Next, to study the SAR of 4′SdNs and
develop 4′SdNs having more potent anti-HIV
activity and less toxicity than 4′MdNs, 4′SdNs
having various kinds of 4′-C-substituents and nucle-
obases were synthesized and evaluated for their
biological activity.9)–16) While we were working on
our project, the anti-HIV activity of several 4′SdNs
Table 1. Anti-HIV activity of 4′-C-methyl-2′-deoxynucleosides
Structure Base EC50 (µM) CC50 (µM) SI (CC50/EC50)
OH
HO
H3C
Base
4'MedN
O Ad 2.6 2.6 1.0
Th 7.2 104
Cy 0.072 0.13 1.8
Purine 1.9 >200 >100
4'Med4N
HO
H3C
Base
O Ad >500 >500 91
Th 21 330 16
Cy 350 350
4'MeddN
HO
H3C
Base
O Ad 30 400 13
Th >500 >500 91
Cy 27 27 1
AZT 0.001 >20 >2020
ddA 47 >500 >11
d4T 4.1 >500 >120
EC50 F 50% eﬀective concentration; CC50 F cytotoxic concentration; SI F selectivity index (CC50/EC50); 4′MdN F 4′-C-methyl-2′-
deoxynucleoside; 4′Md4N F 4′-C-methyl-2′,3′-didehydrodideoxynucleoside; 4′MddN F 4′-C-methyl-2′,3′-dideoxynucleoside; AZT F 3′-
azido-3′-deoxythymidine; ddA F 2′,3′-dideoxyadenosine; d4T F 2′,3′-didehydro-3′-deoxythymidine.
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Scheme 1. General synthetic scheme of 4′-C-substituted-2′-deoxynucleoside (4′SdNs) from D-glucose. 4′SdN F 4′-C-substituted-2′-
deoxynucleoside; 4′MN F 4′-C-methylnucleoside; 4′Md4N F 4′-C-methyl-2′,3′-didehydrodeoxynucleoside; 4′MddN F 4′-C-methyl-
2′,3′-dideoxynucleoside.
Table 2. Anti-HIV activity of 4′-C-substituted-2′-deoxynucleosides
Compound EC50 (mM)a) CC50 (mM) S.I.
4′-C-cyanothymidine 0.002 1 500
4′-C-azidothymidine 0.01 8 300
4′-C-ethynylthymidine 0.83 >400 >482
4′-C-ethynylarabinofuranosylthymine 119 >400 >3.4
4′-C-azidomethylthymidine 2.1 333 159
4′-C-methylthymidine 7.2 104 14
4′-C-ethylthymidine >400 400 ND
4′-C-methoxythymidine 8.49 200 24
4′-C-vinylthymidine >400 >400 ND
4′-C-hydroxymethylthymidine 7.0 >400 >57
4′-C-propylthymidine >100 >100 ND
4′-C-cyano-2′-deoxycytidine 0.0012 0.17 142
4′-C-azido-2′-deoxycytidine 0.004 0.21 52
4′-C-ethynyl-2′-deoxycytidine 0.0048 2.2 458
L-4′-C-ethynyl-2′-deoxycytidine >400 >400 ND
4′-C-ethynyl-2′-deoxy-5-ﬂuorocytidine 0.030 >100 >3333
4′-C-ethynylarabinofuranosylcytidine 0.043 2.0 46.5
4′-C-methyl-2′-deoxycytidine 0.015 1.0 66.7
4′-C-ﬂuoromethyl-2′-deoxycytidine 0.0068 0.12 18
4′-C-methyl-2′-deoxyadenosine 2.6 2.6 1
4′-C-azido-2′-deoxyadenosine 0.13 50 385
4′-C-ethynyl-2′-deoxyadenosine 0.098 16 1630
2′,3′-dideoxy-3′-thia-L-cyrtidine (3TC) 0.10 >100 >1000
3′-azido-3′-deoxythymidine (AZT) 0.0032 29.4 9190
a) Anti-HIV activity was determined by MTT assay. MT-4 cells and HIV-1LAI were employed.
ND: not determined.
Highly anti-HIV active modiﬁed nucleosides No. 3] 57was reported by the Syntex group17)–21) and
others.22),23) Therefore, the anti-HIV activities of
4′SdNs that we studied together with those reported
by other groups are listed in Table 2.
The SARso f4 ′-C-substituted nucleosides
against HIV are summarized as follows:
1. The estimated relative order of anti-HIV activ-
ity is as follows: CN 6 C2CH > N3 >C H F
CH2 >M eF Et > C2C–CH3. Interestingly, the
order is the reverse of the  G
 values between
equatorial and axial substituents on a cyclohex-
ane ring: CN < F < C2CH < CHFCH2 <M e5
Et < tBu. Thus, these results indicate that the
sterically less demanding substituent at the 4′-
position gives more potent anti-HIV activity.
2. Purine analogs are generally less toxic than
pyrimidine. Although 2′-deoxy-4′-C-ethynyl-5-
ﬂuorocytidine, which is a nucleoside derivative
modiﬁed at two positions of physiologic 2′-
deoxycytidine, gave a very acceptable Selectiv-
ity Index (SI F CC50/EC50) with MT-4 cells, it
was toxic with other cells (Kohgo, Yamasa
Corporation, private communication).
3. Arabino analogs are less active and less toxic
compared with their corresponding 2′-deoxy
counterparts.
4. 4′SddNs do not show anti-HIV activity.
5. The L-isomers of 4′SdN have no anti-HIV
activity,14) although it is known that the
L-enantiomer of 2′,3′-dideoxy-3′-thia-L-cytidine
(3TC) is as active as the D-enantiomer and less
toxic than the D-isomer.24) This may be due to
that the L-isomers are too much modiﬁed to be
recognized by RT as its substrates.
Synthesis of purine derivatives of 4′-C-cyano-
2′-deoxynucleoside (4′CNdNs) and 4′-C-ethynyl-
2′-deoxynucleoside (4′EdNs) and their anti-HIV
activity. The mentioned results led us to study the
biological activity of purine derivatives of 4′CNdN
and 4′EdN.25) Although 4′SdNs in our project had
been synthesized by the glycosidation of 4-C-substi-
tuted-D-ribo-furanose derivativesand nucleobases, this
synthetic route incurred some problems, as follows:
1. Preparation of 4-C-substituted-D-ribo-furanoses
and their conversion to the desired 4′SdNs
require multistep reactions, and their total
yields are low.
2. 4-C-Substituited-D-ribo-furanose derivatives
have low reactivity in glycosidation reactions,
especially when the substituent is an electron-
withdrawing group such as a cyano group.
(In contrast, the low reactivity of the anomeric
position of 4-C-substituted furanose derivatives
indicates that 4′SdN will be more stable to
acidic hydrolysis than dN, ddN, and d4N will.)
These problems prompted us to develop another
method of preparing purine derivatives of 4′SdN,
which starts from dNs (Scheme 2).25)
N
N N
N
NH2
O
OH
HO R
N
N N
N
NHBz
O
OH
R
N
N N
N
NHBz
O
OTBS
R
N
N N
N
NHBz
O
OTBS
R
DMTrO
N
N N
N
NHBz
O
OTBS
R
HO
N
N N
N
NHBz
O
OTBS
R
OHC
N
N N
N
NHBz
O
OTBS
R
N
N N
N
NHBz
O
OTBS
R
NC
N
N N
N
NHBz
O
OTBS
R
HO
TBSO
HO
DMTrO
TBSO
HO TBSO
HO
TBSO
(a),(b) (c) (d)
(e) (f) (g)
and
(a):1.TMSCl,py,O°C, 2.BzCl,py,0°C, 3. NH4OH,H2O,0°C, (b):DMTrCl,py,rt, (c): 1.TBSCl,imidazole,DMF,rt,
2.TsOH,H2O,MeOH,CHCl3,0°C, (d): 1.EDCÅEHCl,py, TFA, toluene,DMSO, rt, 2. aq.CH2O,1N NaOH,dioxane,rt, 3.
NaBH4,EtOH,0°C, (e): DMTrCl, Et3N,CH2Cl2,0°C, (f):1.TBSCl,imidazole, DMF, rt, 2. TsOHÅEH2O,MeOH ,CHCl3, rt, 0°C,
(g):EDCÅEHCl,py,TFA,toluene,DMSO,rt.
Scheme 2. Synthetic scheme of purine derivatives of 4′-C-cyano-2′-deoxynucleoside and 4′-C-ethynyl-2′-deoxynucleoside from 2′-
deoxynucleosides. TFA F triﬂuoroacetic acid; DMF F dimethylformamide; rt F room temperature.
H. OHRUI [Vol. 87, 58The biological activities of the purine derivatives
of 4′CNdN and 4′EdN are summarized as follows
(Table 3):
1. Some of the purine derivatives of 4′CNdN have
high anti-HIV activity, but none of them gives
an acceptable SI.
2. All the purine derivatives of 4′EdN have
both high anti-HIV activity and an acceptable
SI.
Anti-HIV activity of 4′SdNs against drug-
resistant HIV mutants.13),14),25) Many 4′SdNs
showed very high anti-HIV activity against wild-
type HIV. However, the most important point of
our study is whether they are active against drug-
resistant HIV-mutants. The anti-HIV activity of
selected 4′SdNs against HIV mutants resistant to
various NRTIs is listed in Table 4.
It isnoteworthy that the three cytidine derivtives
maintained their activity against the drug-resistant
HIV mutants, although the activity of 4′-C-ethynyl
D-arabino-furanosyl cytosine (4′EaraC) and 4′MdC
decreased signiﬁcantly against M184V, M184I, and
Table 3. Anti-HIV activity of purine derivatives of 4′-C-cyano-2′-deoxy (4′CNd) and 4′-C-ethynyl-2′-deoxynucleosides
Structure Base EC50 (µM)a) CC50 (µM) S.I.
OH
HO
NC
O Pu A 0.051 12 235
I 0.051 23 451
2AAb) 0.00079 0.034 43
G 0.000188 0.034 181
HO
OH
O
Pu A 0.098 16 1630
I 0.15 216 1440
2AA 0.0003 0.82 2733
G 0.0014 1.5 975
AZT 0.0032 29.4 9190
a) Anti-HIV activity was determined by MTT assay. MT-4 cells and HIV-1LAI were employed.
b) 2-aminoadenine.
Table 4. Anti-HIV activity of selected 4′-C-substituted-2′-deoxynucleoside against wild type HIV and drug-resistant HIVs
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4'EdC 4'MdC 4'Ed2AA 4'EaraC 4'EdA 4'EdG 4'EdI
Compound
EC50 (µM)a)
HXB2b) KH65R L74V 41/215 M184V M184I
41/69/
125/SG
MDRc) Y181C CC50 (µM)
4′EdC 0.0012 0.0008 0.0013 0.006 0.0024 0.0026 0.015 0.0012 0.0021 >200
4′EaraC 0.0071 0.015 0.026 0.026 0.71 0.48 0.17 0.0079 0.016 >200
4′MedC 0.0058 0.0071 0.0062 ND 0.2 0.74 ND 0.0033 ND >200
4′EdA 0.008 0.0033 0.004 0.012 0.047 0.022 0.065 0.0062 0.011 >200
4′Ed2AA 0.0014 0.00035 0.0007 0.0017 0.0059 0.0027 0.0041 0.001 0.0008 >200
4′EdG 0.007 0.001 0.0012 0.019 0.008 0.0041 0.0068 0.0048 0.01 52
4′EdI 0.81 0.25 0.61 1.3 1.6 1.5 2.2 0.51 ND >200
AZT 0.022 0.02 0.02 0.3 0.01 0.017 1.6 15.3 0.014 >100
3TC 0.71 ND ND ND >100 >100 9.9 1.1 ND >100
ddC 0.2 3.0 1.5 ND 2.2 ND 1.3 5.5 ND >100
ddI 3.9 12.7 19.5 3.6 10.1 ND 12.2 25 ND >100
a) Anti-HIV activity was determined with MAGI assay, ND: not determined. b) wild type HIV. c) multidrug-resistant HIV.
Highly anti-HIV active modiﬁed nucleosides No. 3] 5941/69/125/SG. The three purine derivatives, 2′-
deoxy-4′-C-ethynyladenosine (4′EdA), 2′-deoxy-4′-
C-ethynyl-2-aminoadenosine (4′Ed2AA), and 2′-
deoxy-4′-C-ethynylguanosine (4′EdG) except for 2′-
deoxy-4′-C-ethynylinosine (4′EdI) were highly po-
tent against all drug-resistant HIV-mutants (4′EdI
was much less active than the former three deriva-
tives, especially against M184V). Additionally, the
three were also active against a non-nucleoside reverse
transcriptase inhibitor-resistant Y181C. Further, the
three purine derivatives were highly potent against
the HIVs isolated from seven heavily drug-experi-
enced patients with acquired immune deﬁciency
syndrome (AIDS)a se ﬃciently as against wild-type
HIV.15),16),26) Thus, 4′EdA, 4′Ed2AA, and 4′EdG
were highly potent against all the existing HIVs.
These results let us suppose that the three
purine 4′EdNs could even prevent the emergence of
drug-resistant HIVs. It should be noted that 4′EdG
showed toxicity to Hela cells at 52µM.
Mouse toxicity of purine 4′EdNs. Because
the three purine derivatives of 4′EdNs showed high
activity against all HIVs and acceptable SIs, the
mouse toxicity of these 4′EdNs was next examined
(Table 5).25),26)
All eight mice survived after a single dosage of 3–
100mgkg!1 of 4′EdA and 4′EdI by both intra-
venous and oral administrations, but all mice died
after a single dosage of 3mgkg!1 of 4′Ed2AA and
4′EdG irrespective of the administration method
(Table 5). Thus, it seemed that 4′EA and 4′EI were
not toxic, but 4′E2AA and 4′EdG were highly toxic.
However, in mice, it was found that 4′EdA and
4′Ed2AA were easily converted to 4′EdI and
4′EdG, respectively, by adenosine deaminase.25),26)
These results showed that the actual toxicity of
4′EdA and 4′Ed2AA to animals is hard to estimate.
Anti-HIV activity of 4′EdA derivatives sta-
ble to adenosine deaminase. The fact that both
4′EdA and 4′Ed2AA are deaminated by adenosine
deaminase prompted us to prepare 4′EdA deriva-
tives stable to the enzyme. It has been known that
the adenine derivatives having a halogen atom at
the 2-position of the base are stable to adenosine
deaminase.27),28) Therefore, at ﬁrst, 4′Ed2FA
(Fig. 1) was synthesized and evaluated for anti-
HIV activity28)–31) and stability to both adenosine
deaminase and acidic conditions.
Because 4′Ed2FA is a nucleoside derivative
modiﬁed at two positions (4′-position and 2-position)
of physiologic 2′-deoxyadenosine, the toxicity of
4′Ed2FA is expected to be lower than that of
4′EdA. As shown in Table 6, 4′Ed2FA is highly
potent against all HIVs including multidrug-resistant
and M184V HIV mutants and has an acceptable SI
(110,000).28)–31)
Expectedly, 4′Ed2FA was completely stable to
adenosine deaminase under the conditions where
4′EdA was completely deaminated in 60min and,
further, fairly stable under acidic conditions. Thus, in
120min only a small part (3%) of 4′Ed2FA was
decomposed under the acidic conditions of gastric
juices (pH 1.06) at 24°C, while 2′,3′-dideoxyadenosine
(ddA) was completely decomposed in 5min.
Table 5. Toxicity of purine derivatives of 4′-C-ethynyl-2′-deoxynucleosides to micea)
Intraveneous administration Oral administration
Dose (mg/Kg) Mortality (%) Dose (mg/Kg) Mortality (%)
4′EdA
and
4′EdI
100 0 100 0
10 0 10 0
30 3 0
10 1 0
4′Ed2AA
100 100 (1 day)b) 100 100 (1 day)
10 100 (2 days) 10 100 (2 days)
3 0 3 100 (2 days)
10 1 0
4′EdG
100 100 (1 day) 100 100 (1 day)
10 100 (2 days) 10 100 (4 days)
3 100 (4 days) 3 100 (4 days)
10 1 0
a) Six-week-old ICR male mice were employed.
b) Numbers in parentheses represent survival days of mice after administration.
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OH of 4′EdNs is the cause of the toxicity of
4′EdNs. While we were working on our project, two
papers on the role of 3′-OH of 4′SdNs appeared in
which the authors claimed that 3′-OH was the cause
of the toxicity of 4′SdNs. Tanaka and coworkers
reported32) that 4′-C-ethynyl-2′,3′-didehydro-3′-deox-
ythymidine (4′Ed4T) was more potent against wild-
type HIV and multi-drug resistant HIV mutant but
a little less potent against M184V-mutant and much
less toxic than d4T. Further, they claimed that 3′-
OH of 4′SdNs was the cause of the toxicity.
In contrast, Marquez and coworkers reported33)
that 3′-OH of 4′SdNs played an important role in the
phosphorylation of 5′-OH by cellular kinases, but was
the cause of the toxicity of 4′SdNs. This determi-
nation was based on their results that 4′-C-ethynyl-
2′,3′-dideoxycytidine (4′EddC) was inactive against
HIV in cellular systems, but its 5-O-triphosphate
(4′EddCTP) was more active than 3′-azido-3′-
deoxythymidine-5′-O-phosphate (AZTTP) against
the RT of wild-type HIV. They also reported that
4′EddCTP was much less active against RT of the
M184V mutant than against the RT of wild-type
HIV. In addition, the L-isomer of 4′EddCTP was
not active against the RT of the M184V mutant.
Anti-HIV activity of 2′,3′-dideoxy (dd-) and
2′,3′-didehydrodideoxy (d4) analogs of 4′Ed2FA.
The two papers previously cited caused us to
synthesize the dd- and d4-analogs of 4′Ed2FA and
evaluate their anti-HIV activity.31) The anti-HIV
activities of 2′,3′-dideoxy-4′-C-ethynyl-2-ﬂuoroadeno-
sine (4′Edd2FA)a n d2 ′,3′-didehydrodideoxy-4′-C-
ethynyl-2-ﬂuoroadenosine (4′Ed42FA) together
with that of 2′-deoxy-4′-C-ethynyl-2-chloroadenosine
(4′Ed2ClA) are listed in Table 7.
Although both 4′Ed42FA and 4′Edd2FA
showed some activity against wild-type HIV, they
signiﬁcantly lost any activity against drug-resistant
HIVs. 4′Ed2ClA is highly active against all HIVs,
however, its activity is lower than that of 4′Ed2FA.
These results indicated that the 3′-OH played
important roles not only for the phosphorylation of
5′-OH, but also for the activity against drug-resistant
HIVs. Further, these results together with those
reported by Tanaka and coworkers32) indicated that
the 4′-C-ethynyl group played an important role for
the anti-HIV activity. Recently, it was reported that
the active center of the RT of HIVs has a narrow
lipophylic cavity to accept preferably the ethynyl
group, thus 4′-C-ethynyl nucleoside derivatives have
potent anti-HIV activity.34)
Toxicity of 4′Ed2FA to mice and inhibition
of DNA polymerases. Because 4′Ed2FA is stable
to adenosine deaminase, its mouse toxicity was
examined.29)–31),33),35) 4′Ed2FA did not show any
acute toxicity to mice by either oral or intravenous
administration up to 100mgkg!1 (Fig. 4; Table 8).
It is known that the toxicity of NRTIst o
animals is caused by their inhibition of mitochondrial
DNA polymerase .. The 50% eﬀective concentration
(EC50)o f2 ′-deoxy-4′-C-ethynyl-2-ﬂuoroadenosine-5-
O-triphosphate (4′Ed2FATP) to inhibit the incor-
poration of 2′-deoxyadenosine-5-O-triphosphate
(dATP) mediated by human mitochondrion DNA
polymerase was 10µM, which was signiﬁcantly high-
er than the 0.2µM of 2′,3′-dideoxyadenosine-5-
O-triphosphate (ddATP).30),31),35) The EC50 values
of 4′Ed2FATP against DNA polymerase , and
O were higher than 200µM. These results indicate
that the DNA polymerases scarcely recognize
4′Ed2FATP, a derivative modiﬁed at two positions
of physiologic dATP, as their substrate but that
RT does.
Intracellular metabolism of 4′Ed2FA.29) The
amounts of all fractions of intracellular 4′Ed2FA
Table 6. Anti-HIV activity of 2′-deoxy-4′-C-ethynyl-2-ﬂuoroadenosine (4′Ed2FA)
HIV-1 Compound EC50 (nM) CC50 (nM) SI
Wild-type
4′Ed2AA 0.34 900 2,600
4′Ed2FA 0.068 7,500 110,000
AZT 3.2 29,400 9,190
M184V
4′Ed2FA 3.1
N
N N
N
NH2
O
OH
HO F
4'Ed2FA
m.p. (decomp.)
224.4–224.6°C
[,]D D4.64
(c F 0.5, DMSO)
AZT 16.0
MDR
4′Ed2FA 0.15
AZT 15,300.00
EC50 F 50% eﬀective concentration; CC50 F 50% cytotoxic concentration; SI F selectivity index F CC50/EC50
Highly anti-HIV active modiﬁed nucleosides No. 3] 61metabolites, (4′Ed2FA-monophosphate, 4′Ed2FA-
diphosphate, and 4′Ed2FATP) increased propor-
tionately with an increase in the concentration of
intracellular 4′Ed2FA, while compared to AZT
diphosphate and AZTTP, only AZT monophos-
phate markedly increased with an increase in intra-
cellular AZT concentration. The intracellular half-
life (T1/2)o f4′Ed2FATP was 918h in complete
expansion media (CEM) cells, MT4 cells, and
multinuclear activation of galactosidase indicator
(MAGI)-CCR5 cells (T1/2 of AZTTP was 3h).
About 50% of the cells were protected against
the infection of HIV for 24h after removal of
extracellular 4′Ed2FA in both MT4 cells and
MAGI cells cultured in the presence of 0.1µM of
4′Ed2FA.30),31),36) These results indicate that
4′Ed2FA,2 ′-deoxy-4′-C-ethynyl-2-ﬂuoroadenosine-
5-O-diphosphate (4′Ed2FADP), and 4′Ed2FATP
are very stable against intracellular enzymatic
catabolism.
Summary
A study of the synthesis and biological eval-
uation of 4′SdNs was conducted according to
the proposed working hypotheses based on the
fundamentals of both organic chemistry and bio-
chemistry. All scientiﬁc evidences proved the validity
of the working hypotheses and resulted in the
development of 4′Ed2FA, which is highly potent
against all HIVs, is stable to intracellular enzymatic
catabolism and acidic degradation, has a very long
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Fig. 4. Body weight change of mice after a single dosage of 2′-
deoxy-4′-C-ethynyl-2-ﬂuoroadenosin, administrated orally or
intravenously to ICR mice.
Table 8. Toxicity of 2′-deoxy-4′-C-ethynyl-2-ﬂuoroadenosine
(4′Ed2FA) after a single dosage to ICR mice
Dose (mgKg!1)
Survivors/total
p.o i.v.
Placebo 8/88 /8
18 /88 /8
38 /88 /8
10 8/88 /8
30 8/88 /8
100 8/88 /8
Table 7. Anti-HIV activity of 4′-C-substituted-2′-deoxy-2-haloadenosines
F
N
N N
N
NH2
OH
HO
N
N N
N
NH2
HO
N
N N
N
NH2
HO F F
4'Ed2FA 4'Ed2ClA 4'Ed42FA 4'Edd2FA
O O
N
N N
N
NH2
OH
HO O O Cl HO
4'Ed4T
O
NH
N
O
O
Compound
Anti-HIV activity (MAGI assay, µg)
HIV-1wild HIV-1MDR HIV-1M184V SI
4′Ed2FA 0.00020 0.00014 110,000
4′Ed2ClA 0.0019 0.0084 0.01 330,000
4′Ed42FA 0.80 0.15 1.8
4′Edd2FA 0.94 8.7 97
AZT 0.17 74.3 0.13
3TC 1.0 2.8 >100
4′Ed4T 1.5 1.1 17 >50,000
d4T 7.6 64 5.6
MAGI F multinuclear activation of galactosidase indicator; HIV F human immunodeﬁciency virus; AZT F 3′-azido-3′-deoxythymi-
dine; 3TC F 2′,3′-dideoxy-3′-thia-L-cytidime, d4T F 2′,3′-didehydrodideoxythymidine.
H. OHRUI [Vol. 87, 62intracellular T1/2, does not greatly inhibit DNA
polymerase ., and does not have acute mouse
toxicity.
These results strongly suggest that 4′Ed2FA
deserves further study for the development of a
highly potent therapeutic agent for HIV infection
(AIDS), and which may solve the problems of the
existing HAART.
It should be noted that 4′Ed2ClA is also highly
potent against all HIVs, though it is a little less
potent than 4′Ed2FA, and has better SI than
4′Ed2FA, Therefore, 4′Ed2ClA deserves also for
further study.
The above study together with the recent
studies by others37),38) on the development of anti-
HCV active and/or anti-tumor active modiﬁed
nucleosides which are chain-terminators of RNA
polymerase, prompted the author to propose the
structure of modiﬁed nucleosides expected to have
high antiviral activity and low toxicity.39)
Acknowlegement
The work described in this paper was achieved
through the tremendous eﬀorts of the many co-
workers whose names appear in the cited references.
References
1) Mitsuya, H., Weinhold, K., Furman, P., St Clair, M.,
Lehrman, S., Gallo, R., Bolognesi, D., Barry, D.
and Broder, S. (1985) 3′-Azido-3′-deoxythymidine
(BW A509U): An antiviral agent that inhibits
the infectivity and cytopathic eﬀect of human T-
lymphotropic virus type III/lymphadenopathy-
associated virus in vitro. Proc. Natl. Acad. Sci.
USA 82, 7096–7100.
2) Murphy, E.L., Collier, A.C., Kalish, L.A., Mintz,
L., Wallach, F.R. and Nemo, G.J. (2001) Highly
active antiretroviral therapy decreases mortality
and morbidity in patients with advanced HIV
disease. Ann. Intern. Med. 135,1 7 –26.
3) Hung, C.-C., Hsiao, C.-F., Chen, M.-Y., Hsieh, S.-M.,
Chang, S.-Y., Sheng, W.-H., Sun, H.-Y. and
Chang, S.-C. (2006) Improved survival of persons
with human immunodeﬁciency virus type 1 in-
fection in the era of highly active antiretroviral
therapy in Taiwan. Jpn. J. Infect. Dis. 59, 222–
228.
4) Shuhadonlnik, R.J. (1970) Nucleoside Antibiotics.
Wiley-International, New York.
5) Waga, T., Nishizaki, T., Miyakawa, I., Ohrui, H. and
Meguro, H. (1993) Synthesis of 4′-C-methylnucleo-
sides. Biosci. Biotechnol. Biochem. 57, 1433–1438.
6) Waga, T., Ohrui, H. and Meguro, H. (1996) Syn-
thesis and biological evaluation of 4′-C-methyl
nucleoside. Nucleosides Nucleotides 15, 287–304.
7) Yamaguchi, T., Tomikawa, A., Hirai, T.,
Kawaguchi, T., Ohrui, H. and Saneyoshi, M.
(1997) Antileukemic activities and mechanism of
action of 2′-deoxy-4′-methylcytidine and related
nucleosides. Nucleosides Nucleotides 16, 1347–
1350.
8) Youssefyeh, R.D., Verheyden, J.P.H. and Moﬀatt,
J.G. (1979) Synthesis of 4′-C-hydroxymethyl ribo-
furanosyl nucleosides. J. Org. Chem. 44, 1301–
1321.
9) Kitano, K., Miura, S., Ohrui, H. and Meguro, H.
(1997) Synthesis of 4′-C-ﬂuoromethylnucleosides
as potential antineoplastic agents. Tetrahedron
53, 13315–13322.
10) Kitano, K., Machida, H., Miura, S. and Ohrui, H.
(1999) Synthesis of novel 4′-C-methyl-pyrimidine
nucleosides and their biological activities. Bioorg.
Med. Chem. Lett. 9, 827–830.
11) Kohgo, S., Horie, H. and Ohrui, H. (1999) Synthesis
of 4′-C-ethynyl-O-D-arabino- and 4′-C-ethynyl-2′-
deoxy-O-D-ribo-pentofuranosyl pyrimidines, and
their biological evaluation. Biosci. Biotechnol.
Biochem. 63, 1146–1149.
12) Kohgo, S., Kodama, E., Shigeta, S., Saneyoshi, M.,
Machida, H. and Ohrui, H. (1999) Synthesis of 4′-
substituted nucleosides and their biological evalu-
ation. Nucleic Acids Symp. Ser. 42, 127–128.
13) Ohrui, H., Kohgo, S., Kitano, K., Sakata, S.,
Kodama, E., Yoshimura, K., Matsuoka, M.,
Shigeta, S. and Mitsuya, H. (2000) Synthesis
of 4′-C-ethynyl-O-D-arabino- and 4′-C-ethynyl-2′-
deoxy-O-D-ribo-pentofuranosyl pyrimidines and
-purines and evaluation of their anti-HIV activity.
J. Med. Chem. 44, 4516–4625.
14) Kohgo, S., Mitsuya, H. and Ohrui, H. (2001)
Synthesis of the L-enantiomer of 4′-C-ethynyl-2′-
deoxycytidine. Biosci. Biotechnol. Biochem. 65,
1879–1882.
15) Kodama, E., Kohgo, S., Kitano, K., Machida, H.,
Gatanaga, H., Shigeta, S., Matsuoka, M., Ohrui,
H. and Mitsuya, H. (2001) 4′-Ethynyl nucleoside
analogs: potent inhibitor of multidrug-resistant
human immunodeﬁciency virus variants in vitro.
Antimicrob. Agents Chemother. 45, 1539–1546.
16) Ohrui, H. and Mitsuya, H. (2001) 4′-C-Substituted-
2′-deoxynucleosides: A family of antiretroviral
agents which are potent against drug-resistant
HIV variants. Curr. Drug Targets Infect. Disord.
1,1 –10.
17) Maag, H., Rydzewski, R.M., McRoberts, M.J.,
Crawford-Ruth, D., Verheyden, J.P.H. and
Prisbe, E.J. (1992) Synthesis and anti-HIV activity
of 4′-azido- and 4′-methoxynucleosides. J. Med.
Chem. 35, 1440–1451.
18) O-Yang, C., Wu, H.Y., Fraser-Smith, E.B. and
Walker, K.A.M. (1992) Synthesis of 4′-cyanothy-
midine and analogues as potent inhibitor of HIV.
Tetrahedron Lett. 33,3 7 –40.
19) O-Yang, C., Kurz, W., Eugui, E.M., McRoberts,
M.J., Verheyden, J.P.H., Kurz, L.J. and Walker,
K.A.M. (1992) 4′-Substituted nucleosides as inhib-
itors of HIV: an unusual oxetane derivative.
Tetrahedron Lett. 33,4 1 –43.
Highly anti-HIV active modiﬁed nucleosides No. 3] 6320) Prisbe, F.J., Verheyden, J.P.H. and Rydzewski, R.M.
(1993) 4′-Substituted 2′-deoxy nucleosides as in-
hibitors of HIV. Nucleosides & Nucleotides as
Antitumor & Antiviral Agents (eds. Chu, C.K. and
Baker, D.C.). Plenum Press, New York, pp. 101–
108.
21) Chen, M.S., Suttmann, R.T., Papp, E., Cannon,
P.D., McRoberts, M., Baxh, C., Copeland, W.C.
and Wang, T.S. (1993) Selective action of 4′-
azidothymidine triphosphate on reverse transcrip-
tase of human immunodeﬁciency virus type 1 and
human DNA polymerase alpha and beta. Bio-
chemistry 32, 6002–6010.
22) Wang, G. and Seifert, W.E. (1996) Synthesis and
evaluation of oligodeoxynucleotides containing 4′-
C-substituted thymidines. Tetrahedron Lett. 37,
6515–6518.
23) Nomura, M., Shuto, S., Tanaka, M., Sasaki, T.,
Shigeta, S. and Matsuda, A. (1999) Nucleosides
and nucleotides. 185. Synthesis and biological
activities of 4′-,-C-branched-chain sugar pyrimi-
dine nucleosides. J. Med. Chem. 42, 2901–2908.
24) Beach, J.W., Jeong, L.S.A., Alves, J., Pohl, D., Kim,
H.O., Chang, C.-N., Doong, S.-L., Schinazi, R.F.,
Cheng, Y.-C. and Chu, C.K. (1992) Synthesis of
enantiomerically pure (2′R,5′S)-(!)-1-(2-hydroxy-
methyloxathiolan-5-yl)cytosine as a potent anti-
viral agent against hepatitis B virus (HBV) and
human immunodeﬁciency virus (HIV). J. Org.
Chem. 57, 2217–2219.
25) Kohgo, S., Yamada, K., Kitano, K., Iwai, Y., Sakata,
S., Ashida, N., Hayakawa, H., Nameki, D.,
Kodama, E., Matsuoka, M., Mitsuya, H. and
Ohrui, H. (2004) Design, eﬃcient synthesis, and
anti-HIV activity of 4′-C-cyano- and 4′-C-ethynyl-
2′-deoxy purine nucleosides. Nucleosides Nucleo-
tides Nucleic Acids 23, 671–690.
26) Hayakawa, H., Kohgo, S., Kitano, K., Ashida, N.,
Kodama, E., Mitsuya, H. and Ohrui, H. (2004)
Potential of 4′-C-substituted nucleosides for the
treatment of HIV. Antivir. Chem. Chemother. 15,
169–187.
27) Montgomery, J.A. and Hewson, K. (1969) Nucleosides
of 2-ﬂuoroadenine. J. Med. Chem. 12, 498–504.
28) Brockman, R.W., Schabel, F.M. Jr. and
Montgomery, J.A. (1977) Biologic activity of 9-
O-D-arabinofuranosyl-2-ﬂuoroadenine, a metabol-
ically stable analog of 9-O-D-arabinofuranosylade-
nine. Biochem. Pharmacol. 26, 2193–2196.
29) Patent: International Publication Number, 2005/
090349, PCT/JP2005/005374.
30) Nakata, H., Amano, M., Koh, Y., Kodama, E., Yang,
G., Bailey, C.M., Kohgo, S., Hayakawa, H.,
Matsuoka, M., Anderson, K.S., Cheng, Y.C. and
Mitsuya, H. (2007) Activity against human im-
munodeﬁciency virus type 1, intracellular metab-
olism, and eﬀects on human DNA polymerases of
4′-ethynyl-2-ﬂuoro-2′-deoxyadenosine. Antimicrob.
Agents Chemother. 51, 2701–2708.
31) Kawamoto, A., Kodama, E., Saraﬁanos, S.G.,
Sakagami, Y., Kohgo, S., Kitano, K., Ashida, N.,
Iwai, Y., Hayakawa, H., Nakata, H., Mitsuya, H.,
Arnol, E. and Matsuoka, M. (2008) 2′-Deoxy-4′-
C-ethynyl-2-halo-adenosines active against drug-
resistant human immunodeﬁciency virus type 1
variants. Int. J. Biochem. Cell Biol. 40, 2410–2420.
32) Haraguchi, K., Takeda, S., Tanaka, H., Nitanda, T.,
Baba, M., Dutschman, G.E. and Cheng, Y.-C.
(2003) Synthesis of a highly active new anti-HIV
agent 2′,3′-didehydro-3′-deoxy-4′-ethynylthymi-
dine. Bioorg. Med. Chem. Lett. 13, 3775–3777.
33) Siddiqui, M.A., Hughes, S.H., Boyer, P.L., Mitsuya,
H., Van, Q.N., George, C., Saranﬁnanos, S.G.
and Marquez, V.E.A. (2004) 4′-C-Ethynyl-2′,3′-
dideoxynucleoside analogue, highlights the role of
the 3′-OH in anti-HIV active 4′-C-ethynyl-2′-deoxy
nucleosides. J. Med. Chem. 47, 5041–5048.
34) Boojamra, C.G., Parrish, J.P., Sperandio, D., Gao,
Y., Petrakovsky, O.V., Lee, S.K., Markevitch,
D.Y., Vela, J.E., Laﬂamme, G., Chen, J.M., Ray,
A.S., Barron, A.C., Sparacino, M.L., Desai, M.C.,
Kim, C.U., Cihlar, T. and Mackman, R.L. (2009)
Design, synthesis, and anti-HIV activity of 4′-
modiﬁed carbocyclic nucleoside phosphonate re-
verse transcriptase inhibitors. Bioorg. Med. Chem.
17, 1739–1746.
35) Ohrui, H., Kohgo, S., Kitano, K., Hayakawa, H.,
Kodama, E., Matsuoka, M. and Mitsuya, H. (2005)
4′-C-Ethynyl-2′-deoxy-2-ﬂuoroadenosine, a nucleo-
side derivative potent against HIV-1 with no acute
mouse toxicity: Highlights of the role of 3′-OH
for biological activity. Abstract of the 18th
International Conference on Antiviral Research.
Barcelona, April 10–14, p. 16.
36) Ohrui, H. (2006) 2′-Deoxy-4′-C-ethynyl-2-ﬂuoroade-
nosine, a nucleoside reverse transcriptase inhibitor,
is highly potent against all human immunodeﬁ-
ciency viruses type 1 and has low toxicity. Chem.
Rec. 6, 133–143.
37) Eldrup, A.B., Prhavc, M., Brooks, J., Bhat, B.,
Prakash, T.P., Song, Q., Bera, S., Bhat, N., Dande,
P., Cook, P.D., Bennet, C.F., Carroll, S.S., Ball,
R.G., Bosserman, M., Burlein, C., Colwell, L.F.,
Fay, J.F., Flores, O.A., Getty, K., LaFemina, R.L.,
Leone, J., MacCoss, M., McMaster, D.R.,
Tomassini, J.E., Langen, D.V., Wolanski, B. and
Olsen, D.B. (2004) Structure-activity relationship
of heterobase-modiﬁed 2′-C-methyl ribonucleosides
as inhibitors of hepatitis C virus RNA replication.
J. Med. Chem. 47, 5284–5297.
38) Hattori, H., Tanaka, M., Fukushima, M., Sasaki,
T. and Matsuda, A. (1996) (3-C-Ethynyl-O-D-
ribo-pentofuranosyl)-cytosine, 1-(3-C-Ethynyl-O-
D-ribo-pento-furanosyl)uracil, and their nucleobase
analogs as new potential multifunctional antitu-
mor nucleosides with a broad spectrum of activity.
J. Med. Chem. 39, 5005–5011.
39) Ohrui, H. (2009) A proposed structure of modiﬁed
nucleosides expected to have high antiviral activity
and low toxicity. Nucleosides Nucleotides Nucleic
Acids 28, 772–775.
(Received Nov. 24, 2010; accepted Jan. 14, 2011)
H. OHRUI [Vol. 87, 64Proﬁle
Hiroshi Ohrui was born in 1942. He received his B.S. (1965) and Ph.D. degrees
(1971) from The University of Tokyo under the direction of Professor Masanao Matsui.
He joined the Institute for Physical and Chemical Research (RIKEN) in 1966 as
a researcher. In 1981, he moved to Tohoku University as Associate Professor in the
Department of Food Chemistry, Faculty of Agriculture. In 1997, he was promoted to
Full Professor, Graduate School of Life Science. In 2006, he moved to Yokohama College
of Pharmacy as Professor. He worked for Dr. J. J. Fox at Sloan-Kettering Institute for
Cancer Research (1972–1973) as Research Associate, and for Dr. J. G. Moﬀatt at Syntex
Research (1973–1974) as a postdoctoral fellow. He has received several awards including
The Agricultural Society of Japan Award for Young Scientists (1974), Inoue Prize for
Science (2001), Japan Prize of Agricultural Sciences (2004), The Japan Society for Analytical Chemistry Award
(2004), and the Japan Academy Prize (2010). His research interests cover organic synthesis, chiral discrimination,
and medicinal chemistry.
Highly anti-HIV active modiﬁed nucleosides No. 3] 65